In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 8 days of free consultation


Prevalence of methylene blue non-responders among patients with vasoplegic shock after cardiopulmonary bypass surgery

Session Moderated Poster 1: Interventional cardiology

Speaker Felipe Canas

Congress : Acute Cardiovascular Care 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Interventional Cardiology - Other
  • Session type : Moderated Posters
  • FP Number : 33

Authors : F Canas (Cali,CO), NA Florez (Cali,CO), DF Bautista (Cali,CO), GC Giraldo-Gonzalez (Cali,CO)


F Canas1 , NA Florez1 , DF Bautista2 , GC Giraldo-Gonzalez1 , 1Valle del Lili Foundation, Cardiología - Cali - Colombia , 2Valle del Lili Foundation, Unidad de Cuidado Intensivo - Cali - Colombia ,


Title: Prevalence of methylene blue non-responders among patients with vasoplegic shock after cardiopulmonary bypass surgery.
Background/Introduction: vasoplegic shock occurs up to 44% of patients after cardiopulmonary bypass surgery (CBS). Methylene blue (MB) among other vasopressors can increase mean arterial pressure after CBS. Retrospectively, receiving MB has been related to improved survival. The greatest response to MB is observed at the 8th hour of administration, as a significant decrease in the dose of vasopressors.
Purpose: to describe the prevalence and characteristics of MB non-responders among patients with vasoplegic shock after CBS.
Methods: All consecutive patients from January 2017 to May 2018 taken to CPB surgery and were alive at 48 hours of surgery where analysed retrospectively. All patients that received MB were included. Demographic characteristics, clinical and laboratory data was obtained from medical records. The dose of vasopressors received was summarized by vasoactive inotropic score (VIS). MB was systematically administered to patients who had received adequate fluid resuscitation and persisted hypotensive despite 0,4 µg/kg/min of norepinephrine plus 2,4 UI/hr of vasopressin and one inotropic (VIS > 40). Responders to methylene blue were defined as those with a reduction in VIS greater than 50% at the 8th hour after MB administration.
Results: Among 202 of patients included, 8 % (n = 16) patients developed vasoplegic shock and received MB. Most patients (62%, n = 10) were responders to MB. There was not significant demographic differences between responders vs non-responders, neither significant differences in the prevalence of known risks factors for vasoplegic shock. MB maximal hemodynamic response was observed at 8th hour form application (Table 1 and Figure 1.). MB responders had higher cardiac index and systemic vascular resistance index. There was no differences in incidence of infection between responders vs non-responders. Remarkable, non-responders had higher leukocytes count in the first 48 hours.
Conclusion: MB is an effective treatment of VS after cardiac surgery, but 40% of our cohort did not respond to therapy.

Variable Total Responders Non - responders P
ECC (min) 112 ± 41 105 ± 46 124 ± 33 NS
Time between end of ECC and MB administration (hours) 2 [1 - 10] 2 [1 - 75] 3 [1 - 49] NS
VIS at MB administration 63 [43 - 87] 66 [44 - 87] 63 [35 - 95] NS
VIS at 8th after MB 25 [18 - 52] 19 [6 - 24] 61 [42 - 89] <0,0001
Expressed as mean ± SD, or median [IQR] as appropriate. ECC: extracorporeal circulation, MB: methylene blue, VIS: Vasoactive Inotropic Index

This content is currently on FREE ACCESS, enjoy another 8 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are